Triple therapy: Phaco-vitrectomy with ILM peeling, retinal endophotocoagulation, and intraoperative use of Bevacizumab for diffuse diabetic macular edema

Jacek Robaszkiewicz, Katarzyna Chmielewska, Małgorzata Figurska, Joanna Wierzbowska, Andrzej Stankiewicz

Department of Ophthalmology, Military Institute of Medicine in Warsaw, Warsaw, Poland

Source of support: Departmental sources

Summary

Background: The aim of this study was to evaluate the visual acuity and structural outcomes of combined phaco-vitrectomy with ILM peeling, retinal endophotocoagulation and use of bevacizumab in patients with diffuse diabetic macular edema (DDME).

Material/Methods: In this prospective, nonrandomized, interventional study we included 29 eyes of 26 patients with DDME. The best-corrected visual acuity (BCVA) and central retinal thickness and volume (CRT and CRV) were recorded at 4, 8, 12, and 16 months after surgery.

Results: The mean preoperative BCVA was 0.74±0.36 logMAR (0.3–1.5) and improved finally to 0.4±0.24 logMAR (0.1–1.0) p=0.000006. The mean preoperative CRT in the 1mm zone was 516±184 µm (256–950) and decreased postoperatively at the last control to 237±75 µm (117–489) p=0.000003. The mean preoperative CRV in the 1mm zone was 0.39±0.14 µL (0.19–0.74) and decreased postoperatively at the last control to 0.17±0.06 µL (0.09–0.36) p=0.000003. The mean preoperative CRT in the 6 mm zone was 407±105 µm (279–640) and decreased postoperatively at the last control to 282±40 µm (212–380) p=0.000004. The mean preoperative CRV in the 6 mm zone was 11.4±2.9 µL (7.85–17.93) and decreased postoperatively at the last control to 7.92±1.0 µL (5.62–10.97) p=0.000003. The 23 (79.3%) eyes showed improvement in BCVA ≥0.2 logMAR, 5 (17.2%) eyes improvement or stabilization of BCVA and 1 (3.5%) eye deterioration. Preoperative BCVA was a positive factor for prognosis of BCVA at 12th month follow-up (b=0.42; p=0.006), while the negative factors were: previous panretinal photocoagulation (b=–0.24; p=0.04), presence of vitreomacular traction (b=–0.29; p=0.02) and preoperative CRT in the 1000 µm zone (b=–0.24; p=0.07). A greater visual acuity improvement occurred in eyes with worse baseline visual acuity (b=–1.01; p=0.000001). The presentation of vitreomacular traction (b=–0.38; p=0.02), previous panretinal photocoagulation (b=–0.31, p=0.04) and greater preoperative CRT in the 1000 µm zone (b=–0.31; p=0.07) were negative factors for visual improvement.

Conclusions: This combined treatment resulted in improvement or stabilization of BCVA and decrease of CRT and CRV. Larger comparative studies are necessary to establish the real impact of this therapeutic approach.

key words: diffuse diabetic macular edema (DDME) • vitrectomy • ILM peeling • anti-VEGF injection • endophotocoagulation

Full-text PDF: http://www.medscimonit.com/fulltxt.php?ICID=882624

Word count: 4146

Tables: 5

Figures: 17

References: 40

Author’s address: Jacek Robaszkiewicz, Department of Ophthalmology, Military Institute of Medicine in Warsaw, Szaserów 128 St., 00-909 Warsaw, Poland, e-mail: jrobaszkiewicz@wim.mil.pl
Background

Macular edema is the main vision-limiting factor in diabetes and is a disorder of increasing public health importance throughout the world [1]. Diffuse macular edema results from a generalized breakdown of the blood-retinal barrier with intra- and subretinal accumulation of fluid. Based on observations of the Early Treatment of Diabetic Retinopathy Study Group, laser photocoagulation can decrease the rate of moderate visual loss up to 50%; however, visual improvement is uncommon (3–14.5%) in DME [2]. Moreover, outcomes with laser treatment in diffuse diabetic macular edema are more unfavorable and some eyes have persistent edema and visual loss. This fact has led investigators to seek alternative modalities for the management of DDME, such as administration of steroids, protein kinase C (PKC) inhibitors or vascular endothelial growth factor (VEGF) inhibitors by intravitreal injections. The pharmacotherapeutic approach is under investigation to determine if certain drugs, either alone or in combination with focal/grid laser, result in superior visual acuity outcomes compared with laser alone.

VEGF is involved in pathogenesis of diabetic macular edema [3,4] and recently anti-VEGF agents such as bevacizumab and ranibizumab have been shown to be beneficial in the treatment of this retinal disorder [5–8]; however, endogenous VEGF is required for visual function. A growing body evidence indicates that VEGF also acts on nonvascular cells; it plays a survival role in Müller cells and photoreceptors [9]. Therefore, anti-VEGF therapies should be administered with caution and not in a permanent manner. Photocoagulation in nonperfused areas eliminates increased production of VEGF, induces proliferation of RPE and increases production of PEDF in the surrounded impact laser area [10].

Posterior hyaloids [11–13] play an important role in the development of diffuse macular edema. The observation that the release of mechanical traction on the macula with subsequent reduction in DME, either by spontaneous posterior vitreous detachment or with vitrectomy, lends support to this line of reasoning [14–16]. A proper understanding of the anomalous posterior vitreous detachment (APVD) is essential for the development of an efficient strategy in treatment of diabetic maculopathy. It is possible that subclinical vitreoretinal traction on the macula exists in a large number of individuals with diabetes and may exert subclinical but significant traction on the compromised diabetic macular vascular bed and cause macular edema. The natural course of the disease leads to the fusion of intraretinal spaces in the macula and formation of a partial-thickness (Figure 1), and finally a full-thickness, extensive macular hole (Figure 2). Fibrovascular proliferations over the retinal surface can lead to retinoschisis of the macula, which, due to the lack of microvascular scaffold, is especially susceptible to tractions. (Figure 3).

It is important for the surgeon to determine the factors that might influence surgical outcome so that patients who can benefit most are chosen for the procedure. We therefore evaluated the possible preoperative and intraoperative factors that might influence surgical outcomes.

Material and Methods

A prospective nonrandomized study was conducted at the Department of Ophthalmology Military Institute of Medicine in Warsaw (Poland) between September 2008 and September 2010. The study included 29 eyes of 26 patients with DDME that had recurrent or persistent macular edema after laser photocoagulation. The study was conducted under bioethical committee permission, as injection of bevacizumab into the vitreous cavity is an off-label use. All patients provided written informed consent.

The project has been positively assessed and registered with Clinical Trials (ClinicalTrials.gov Identifier: NCT01218750).

Inclusion criteria were

1. Diagnosis of DDME upon clinical exam, definite retinal thickening involving the center of the macula, confirmed by fluorescein angiography, with or without PVD;
2. BCVA of 0.3 or worse in logMAR units (≤70 ETDRS letter) and 1.5 or better in logMAR units (≥10 ETRDS letter);
3. Mean central macular thickness greater than 250 µm on optic coherence tomography (OCT);
4. Presence of vitreomacular traction, or a thickened and taut posterior hyaloids, or presence of an epimacular membrane.

Exclusion criteria were

1. Significant macular ischemia defined as enlarged perifoveal capillary loss (≥3 mm²) by fluorescein angiography;

Figure 1. Partial-thickness macular hole formations during long-lasting diabetic macular edema.
2. Focal macular edema due to focal leakage from microaneurysm;
3. Ophthalmic disorders associated with macular edema, such as uveitis, branch or central retinal vein occlusion and pseudophakic cystoid macular edema;
4. Vitreous hemorrhage or tractional retinal detachment secondary to diabetic retinopathy;
5. An ocular condition is present such that visual acuity would not improve from resolution of macular edema (e.g., foveal atrophy, pigmentary abnormalities, dense subfoveal hard exudates);
6. History of retinal macular photocoagulation, intravitreal corticosteroids, or other treatment for DME within the 3 months prior to enrollment;
7. History of any intraocular surgery within the prior 6 months.

The examination included the following elements: the best corrected visual acuity (BCVA) for ETDRS chart, measurement of intraocular pressure, slit lamp biomicroscopy with iris examination and lens status by LOCS, retinopathy stage by stereo examination of the posterior pole with dilatation of the pupil, history of laser photocoagulation, intravitreal corticosteroids, or other treatment for DME within the 3 months prior to enrollment;

The demographic characteristics of the patients including age, gender, metabolic condition, HbA1c level, body mass index, presence of systemic hypertension and ocular status, diabetic retinopathy stage, and previous laser are shown in Table 1. Three-port pars plana vitrectomy was performed in all patients by 1 surgeon (JR). Induction of PVD, if not present, was initiated by active suction with the vitrectomy probe over the ONH and continued peripherally (Figure 4). Triamcinolone

Table 1. Characteristics of study eyes.

| Gender, M: F | 11: 15 |
| Age | 59±13.8 range: 27–78 |
| HbA1c | 8.03 range: 6.9–9.4 |
| BMI | 28.45 range: 20.44–41.0 |
| Hypertension no. of patients | 24 |
| Stage of DR, NPDR: PDR | 16: 13 |
| Preoperative laser treatment FML: PRP | 10: 19 |
| Previous cataract surgery IOL: fakic | 8: 21 |

HbA1c — glycated hemoglobin A1c; BMI — body mass index; DR — diabetic retinopathy; NPDR — nonproliferative diabetic retinopathy; PDR — proliferative diabetic retinopathy; PRP — panretinal photocoagulation; FML — focal macular laser.

clinically significant reduction of the central retinal thickness was defined as a reduction of at least 10% of thickness of the central retina. Diagnosis of PVD was made by OCT and supported intraoperatively if there were no vitreous cortex remnants left at the posterior pole that could have been separated from the macula and optic nerve head by suction with the vitrectomy probe.

The demographic characteristics of the patients including age, sex, metabolic condition, HbA1c level, body mass index, presence of systemic hypertension and ocular status, diabetic retinopathy stage, and previous laser are shown in Table 1.

Three-port pars plana vitrectomy was performed in all patients by 1 surgeon (JR). Induction of PVD, if not present, was initiated by active suction with the vitrectomy probe over the ONH and continued peripherally (Figure 4). Triamcinolone
was used in all the patients only as a marker in order to visualize and removal of vitreous schisis (Figure 5). Triamcinolone was fully washed out of the eyeball during the surgery. Peeling of the epimacular tissue and ILM was performed by grasping the flap of the ILM with an Eckardt forceps (Figure 6). In difficult cases of the incipient macular detachment, stabilization of the retina in the posterior pole with perfluorocarbon was performed (Figure 7). Trypan Blue was used to stain the ILM. Peripheral laser photocoagulation was performed in cases of avascular areas based on FA, active neovascularization, peripheral retinoschisis or retinal breaks. Shaving of the peripheral vitreous body on the basis and sites of sclerotomies was very important on successfull the surgery (Figure 8). Then a exchange fluid/air was performed by infusion and passive aspiration with the softcaniule (Figure 9). All eyes had 1.25 mg/0.05 ml of bevacizumab injected into the vitreous cavity (Figure 10) and a SF6 gas tamponade at the end of the procedure. Even in the absence of a cataract formation, a combined procedure was performed because of exact peripheral vitreous sheaving and prevention of cataract formation.

Figure 4. Posterior vitreous detachment induction by active suction with the vitrectomy probe.

Figure 5. Triamcinolone usage for better visualization remnants of the hyaloids and epiretinal membranes on the posterior pole.

Figure 6. The removal of the epiretinal membranes by bimanual technique with an Eckardt forceps and horizontal knife.

Figure 7. In difficult cases of the incipient macular detachment, stabilization of the retina in the posterior pole with perfluorocarbon was performed.
During follow-up, bevacizumab injection into the vitreous cavity and macular laser photocoagulation were conducted sequentially in case of macular edema recurrence. The injections were performed using sterile technique, 3.5 mm posterior from limbus in the inferotemporal quadrant. In the refractory cases with intraretinal cyst formation, the 25-gauge vitrectomy with drainage of the fluid from the cyst using MVB and silicone soft-tip cannula was performed. Macular laser photocoagulation was performed directly to leaking microaneurysms in areas of retinal thickening between 500 and 3000 microns from the center of the macula and applied to all areas with edema not associated with microaneurysms. We used green diode laser VISULAS with wavelength of 532 nm, burn size 100 µm, burn duration 0.05 to 0.1 sec and enough intensity for barely visible impact.

Statistical analysis

The ANOVA rank Friedman test was used for comparison of pre- and postoperative visual acuities and central retinal thickness and volume. Multiple regression analysis was performed to evaluate the possible relationship of preoperative BCVA, preoperative central macular thickness and volume, preservation of os/is line, presentation of serous macular detachment, enlargement of FAZ, lens status, diabetic retinopathy stage, and history of laser photocoagulation with a change in postoperative BCVA, CRT in the 1000 µm zone at 12th month follow-up, visual and structural improvement.

Results

Before surgery, 19 (65.5%) eyes had previous panretinal photocoagulation, 10 eyes (34.5%) had previous macular laser photocoagulation, 7 eyes (24.1%) had vitreomacular traction, 15 eyes (51.7%) had presence of epiretinal membrane, 5 eyes (17.2%) had serous macular detachment and 2 eyes (6.9%) had macular hole.

The mean (range) preoperative best corrected visual acuity (BCVA) was 0.74±0.36 logMAR (0.3–1.5), postoperative BCVA was 0.48±0.29 logMAR (0.04–1.1), p=0.000003, 0.43±0.28 logMAR (–0.02–0.9), p<0.000001, 0.42±0.29 logMAR (–0.01–0.9), p<0.000001.
The mean (range) preoperative central macular volume (CRV) in the 1 mm zone was 0.39±0.14 µL (0.19–0.74) and decreased significantly to 0.25±0.08 µL (0.09–0.55), p=0.00006, 0.2±0.06 µL (0.08–0.3), p=0.000005, 0.21±0.08 µL (0.08–0.46), p=0.00015 4, 8, and 12 months postoperatively (Figure 13). The mean (range) preoperative central macular volume (CRV) in the 6 mm zone was 11.4±2.88 µL (7.85–17.93) and significantly decreased to 8.75±1.0 µL (7.13–11.45), p=0.000023, 8.46±1.18 µL (6.38–11.59), p=0.000005, 8.35±1.4 µL (6.36–13.01), p=0.000007 4, 8, and 12 months postoperatively (Figure 14).

A statistically significant structural improvement occurred in all periods of observation. A clinically significant reduction, defined as a reduction of at least 10% of thickness of the central retina in the 1 mm zone, occurred on the 4th and 8th month in 25 out of 29 eyes (86.4%), after 12 months in 22 out of 29 eyes (75.9%), after 16 months in 19 out of 22 eyes (86.4%), and after 20 months in 11 out of 13 eyes (84.6%).

A reduction of at least 30% of the thickness of the central retina in the 1 mm zone occurred on the 4th and 12th month
in 16 out of 29 eyes (55.2%), after 8 months in 18 out of 29
eyes (62%), after 16 months in 14 out of 22 eyes (63.6%),
and after 20 months in 6 out of 13 eyes (46.1%).

Preoperative best-corrected visual acuity (BCVA) was neg-
avatively correlated with the average central retinal thick-
ness and volume in the 6000 µm zone (r=–0.65, r=–0.63,
p<0.0001). There was also a negative correlation with
these structural parameters of the retina in the 1 mm zone
(r=–0.59, p=0.001) (Figure 15).

In the 4th month of observation, the BCVA did not express
statistically significant correlation with the CRT and CRV
in both of the zones.

In the 8th month of observation the best BVCA had a posi-
tive correlation with the average CRT and CRV only in the
1 mm zone (r=0.54, p=0.003 and r=0.55, p=0.002). No cor-
relation was found with the 6 mm zone (Figure 16).

In the 12th month of observation the BCVA was character-
ized by a worse than in the 8th month positive correlation
with the CRT and CRV in the 1 mm zone (r=0.38, p=0.04
and r=0.4, p=0.033) (Figure 17).

In the 16th month of observation the 22 controlled eyes
showed no correlation of the BCVA with average central
retinal thickness or with average central retinal volume in
both of the zones.

The anatomical relations of the central retinal characteristic
of the eyes included in the study showed that the preoperative
CRT was characterized by a strong positive correlation with
the CRV in both the 1 mm and 6 mm zones (r=0.99, p<0.0001).

During the postoperative period a sustained strong posi-
tive correlation between the central retinal thickness and
volume in both the 1 mm and 6 mm zones was observed
(r=0.95−0.99, p<0.001 and r=0.97−0.99, p<0.001).

During the follow-up period, deterioration (0.24 logMAR)
of BCVA was noted only in 1 eye (3.4%). The cause for de-
teriation was vitreous hemorrhage and secondary glau-
coma. Two eyes (6.89%) had mild vitreous hemorrhage which
resolved spontaneously at 2–4 weeks, 1 eye (3.4%) had se-
rious macular detachment, and 2 eyes (6.89%) had posteri-
or capsule opacifications. No eye had complications such as
iris neovascularization, retinal detachments, or endophthal-
mitis during the follow-up period.
Postoperatively, 28 injections of bevacizumab into the vitreous cavity of 14 eyes were reported (max. 3 injections per eye). Focal macular laser was applied at 1 week after injection. In 2 eyes (6.89%) an additional 25-gauge vitrectomy with drainage of the fluid from the macular cyst was performed.

Preoperative BCVA was positively associated with preservation of os/is line between outer/inner segments of the photoreceptors ($b=0.67; p=0.000001$) and the serous macular detachment ($b=-0.05; p=0.01$) (Table 2).

Greater central retinal thickness in region 1000 µm ($b=-0.24; p=0.07$) were negative factors for visual improvement (Table 4).

Greater reduction in central retinal thickness occurred with greater preoperative central retinal thickness in the 1000 µm zone ($b=-0.31; p=0.07$) and greater preoperative CRT in the 1000 µm zone ($b=-0.31; p=0.07$) (Table 4).

Greater visual acuity improvement occurred in eyes with worse baseline acuity ($b=1.01; p=0.00001$). The presentation of vitreomacular traction ($b=-0.31; p=0.04$) and greater preoperative CRT in the 1000 µm zone ($b=-0.31; p=0.07$) were negative factors for visual improvement (Table 4).

Greater structural improvement was not correlated with greater visual acuity improvement.

**DISCUSSION**

The accumulation of advanced glycation end-products, retinal tissue hypoxia, diabetic disorder of hemostasis leading to the breakdown of the blood-retina barrier, induce diabetic retinopathy [17–19] and pathological processes in the vitreomacular interface [20,21]. Particularly important changes occur in the glial cells of the retina and in the vitreous collagen fibers [22,23]. The pathological process of posterior vitreous detachment leads to vitreouschisis, epiretinal membranes, tractions and macular hole formation. This requires surgical removal of the internal retinal membrane (ILM), guaranteeing the total removal of the epiretinal proliferations, which may improve oxygenation of the inner layers of the retina and stimulates intraretinal gliosis [24].

In 1992 Lewis et al. [14] first reported vitrectomy as an alternative treatment for diffuse DME associated with posterior

---

**Table 2.** Multiple regression analysis evaluating the relationship of preservation of os/is line, presentation of serous macular detachment (SMD), preoperative central retinal thickness (CRT 6000) and presentation of vitreomacular traction (VMT) with a chance in preoperative BCVA.

|                | Preoperative BCVA (ETDRS letter) |
|----------------|----------------------------------|
|                | $R=0.9149845 R^2=0.83719655 R^2=0.81006264$ |
|                | F(4,24)=30.854 p<.00000 Std. estim. error: 8.0201 |
| $n$            | 29                               |
| $b$            | SD $b$                           |
| os/is line     | 0.67 0.10                        |
| SMD            | 0.26 0.08                        |
| CRT6000 preop. | $-0.28 0.08$                    |
| VMT            | $-0.17 0.08$                     |
| $p$            |                                  |
|               | 0.000001                          |

**Table 3.** Multiple regression analysis evaluating the relationship of preoperative BCVA, panretinal photocoagulation (PRP), presentation of VMT and preoperative central retinal thickness 1000 µm (CRT 1000) and with a chance in postoperative BCVA on the 12th month.

|                | BCVA 12 months (ETDRS letter) on the 12th month |
|----------------|-----------------------------------------------|
|                | $R=0.8736453 R^2=0.76325564 R^2=0.72021121$ |
|                | F(4,22)=17.732 p<.00000 Std. estim. error: 7.8499 |
| $n$            | 29                                            |
| $b$            | SD $b$                                       |
| Preop. BCVA    | 0.42 0.14                                    |
| PRP            | $-0.24 0.11$                                 |
| VMT            | $-0.29 0.11$                                 |
| Preop. CRT 1000| $-0.24 0.12$                                 |
| $p$            |                                         |
|               | 0.000002                                      |
hyaloid traction. It was used thereafter for management of DME even in the absence of vitreomacular adhesion [25–28]. In 2007 Patel et al. [29], in a prospective, comparative study of PPV with and without ILM peeling for diffuse clinically significant macular edema, reported better structural improvement but with limited visual improvement after ILM peeling compared with leaving ILM. In our opinion, PPV with separation of the posterior hyaloid without ILM peeling in eyes with diabetic macular edema relieves only antero-posterior tractions and edema resolved for a limited time because of an epimacular membrane formation. Vitrectomy including removal of the ILM leads to resolution of diffuse diabetic macular edema and improvement of visual acuity, and prevents subsequent epiretinal membrane formation. Complete release of tractional forces and inhibition of cellular proliferation seem to be prudent in the eyes of patients with diabetes. We suggest that retinal traction by the posterior hyaloid membrane is involved in the pathogenesis of cystoid changes in diabetic patients. Furthermore, the evidence that vitrectomy produces improved retinal oxygenation [30], taken together with the evidence that increased oxygenation can reduce DME [31], suggests an additional physiologic advantage potentially conferred by vitrectomy. Removed ILM contains a part of the Müller cell end-feet and the horizontal gliosis [32]. It is likely that the proliferation of GFAP-stained gliofibrils, observed in damaged Müller cells, preserves the blood-retinal barrier, reinforces architectural cohesion, and opposes the installation of the edema. Therefore, we confirmed the hypothesis that combined triple therapy was effective for decreasing macular thickness and improvement of vision for eyes with diffuse diabetic macular edema. In 2007, Kang et al. [33] reported on triple therapy, which included vitrectomy with subsequent triamcinolone injection into the vitreous cavity, and macular laser photocoagulation. The major adverse events after this therapy included the development of nuclear sclerotic cataracts (8 among 12 phakic eyes) and elevation of intraocular pressure (8 among 24 eyes). In our opinion, this strategy may facilitate early recovery of vision, but the long-term outcomes may be improved by additional lens exchange to eliminate cataract formation. Anti-VEGF usage instead of triamcinolone can prevent the intraocular pressure from increasing.

Table 4. Multiple regression analysis evaluating the relationship of preoperative BCVA, panretinal photocoagulation (PRP), presentation of VMT, preoperative central retinal thickness 1000µm (CRT 1000) with a chance in improvement of BCVA on the 12th month.

| N=29 | Improvement of BCVA (ETDRS letter) on the 12th month | b* | SD b* | b | SD b | p |
|-------|---------------------------------------------|-----|-------|----|------|---|
| Preop. BCVA | –1.01 | 0.17 | –0.65 | 0.11 | 0.000011 |
| PRP | –0.31 | 0.14 | –7.35 | 3.46 | 0.045453 |
| VMT | –0.38 | 0.15 | –9.87 | 3.97 | 0.021139 |
| Preop. CRT 1000 | –0.31 | 0.16 | –0.02 | 0.01 | 0.073487 |

Table 5. Multiple regression analysis evaluating the relationship of preoperative central retinal thickness (CRT 1000), lens status (STK), presentation of VMT and SMD with a chance in central retinal thickness 1000 µm (CRT 1000) reduction on the 12th month.

| N=29 | Reduction of CRT 1000 (µm) on the 12th month | b* | SD b* | b | SD b | P |
|-------|---------------------------------------------|-----|-------|----|------|---|
| Preop. CRT 1000 | 0.77 | 0.11 | 1.02 | 0.14 | 0.000000 |
| Lens status (STK) | 0.22 | 0.10 | 110.92 | 51.55 | 0.042 |
| VMT | 0.15 | 0.10 | 78.82 | 53.10 | 0.15 |
| SMD | 0.14 | 0.11 | 79.30 | 66.50 | 0.24 |
After vitrectomy, clearance is accelerated and VEGF concentrations are reduced [34]. Therefore, we performed injections of bevacizumab only a few days before macular grid/focal photocoagulation in cases of macular edema recurrence during follow-up. We observed resolution of diabetic macular edema and improvement of visual acuity in post-vitrectomized eyes and occasionally we observed an effect on the non-injected fellow eyes. This fact confirms the systemic action of bevacizumab after vitreous cavity delivery and seems to be correlated with the intensity of the hyperfluorescence by fluorescein angiography.

Our study confirms observations that visual acuity is positively associated with preservation of the line between outer/inner segments of the photoreceptors [35]. An interesting observation is, that serous retinal detachment in the macular area positively correlated with preoperative visual acuity. This may be due to the preservation of the integrity of the synaptic connections in the neurosensory retina, raised in contrast to the swollen tissue, where there is a separation of retinal layers by accumulation of the edematous fluid. The negative factors were presentation of vitreomacular traction (VMT) and greater preoperative retinal thickness. The obtained results of functional improvement, reduction of central retinal thickness, and the removal of vitreoretinal interface pathology suggest that the combined therapy is effective and, if performed early, gives very good functional and structural results. The visual functionality of eyes with diabetic maculopathy had statistically significant improvement in all periods of observation, with an upward trend over time. This method has a high therapeutic value as it improves the treatment results of the currently practiced monotherapies and combination therapies [38].

This combined treatment can be an effective method of restoring macular structure and may improve visual acuity for eyes with persistent DME after laser photocoagulation, even in eyes without vitreomacular traction. If we want to treat diabetic maculopathy more effectively, it is necessary to replicate the 2 components of a physiological PVD: gel liquefaction and vitreo-retinal dehiscence. Pharmacologic therapy with use of anti-VEGF agents supports short-term tightness of the blood-retina barrier in the perioperative period and reduces macular thickness before focal/grid laser treatment. This not only facilitates surgery, but, if performed early in the natural history of the disease in conjunction with laser treatment, it should prevent progression of the focal macular edema and may delay surgical treatment. Unfortunately, in the absence of posterior vitreous detachment, pathological changes on the vitreomacular interface need en-block removal of tractions, epimacular proliferations and thickened ILM. Complete removal of ILM reduces the risk of horizontal proliferation on the retina, while it induces intraretinal-vertical gliosis. The existence of these 2 gliosia types was shown in the research of Yvette i Dieter Ducournau [39]. The horizontal gliosis is connected to proliferation of astrocytes and Müller’s cells on the internal surface of the retina that subsequently leads to formation of epiretinal membranes. Vertical gliosis is connected to hypertrophy of Müller’s cells. Our aim is induction of vertical gliosis, while minimizing the gliosis on the retina’s surface. The effect of reactive, vertical gliosis after ILM removal allows for maintaining the blood-retina barrier and prevents macular edema installation. Wolf et al. [40] performed retinal histology via electron microscope after the internal limiting membrane was removed and demonstrated that a significant part of the Müller’s cells endings had been damaged. Their main bodies, however, did not show signs of damage. It is likely that the proliferation of GFAP-stained gliofibrils, observed in damaged Müller’s cells, preserves the blood-retinal barrier, reinforces architectural cohesion, and opposes the installation of the edema. Without question, a serious flaw connected with leaving parts of the ILM during vitrectomy is increased risk of developing secondary macular pucker syndrome.

Simultaneous endophotocoagulation based on an angiography map allows for the elimination of areas with capillary nonperfusion, which are a source for the synthesis of vascular endothelial growth factor (VEGF). The intraoperative use of anti-VEGF reduces the risk of an increase of the macular edema in the perioperative period. The surgical trauma may increase the macular edema; therefore, during this critical phase it is advisable to utilize a protective anti-VEGF therapy to reduce the edema. As the intraretinal gliosis is a slow process, the anti-VEGF injections must be continued.

**Conclusions**

The obtained results of functional improvement, reduction of central retinal thickness, and the removal of vitreoretinal interface pathology suggest that the combined therapy is effective and, if performed early, gives very good functional and structural results. The visual functionality of eyes with diabetic maculopathy had statistically significant improvement in all periods of observation, with an upward trend over time. This method has a high therapeutic value as it improves the treatment results of the currently practiced monotherapies and combination therapies [38]. This combined treatment can be an effective method of restoring macular structure and may improve visual acuity for eyes with persistent DME after laser photocoagulation, even in eyes without vitreomacular traction. If we want to treat diabetic maculopathy more effectively, it is necessary to replicate the 2 components of a physiological PVD: gel liquefaction and vitreo-retinal dehiscence. Pharmacologic therapy with use of anti-VEGF agents supports short-term tightness of the blood-retina barrier in the perioperative period and reduces macular thickness before focal/grid laser treatment. This not only facilitates surgery, but, if performed early in the natural history of the disease in conjunction with laser treatment, it should prevent progression of the focal macular edema and may delay surgical treatment. Unfortunately, in the absence of posterior vitreous detachment, pathological changes on the vitreomacular interface need en-block removal of tractions, epimacular proliferations and thickened ILM. Complete removal of ILM reduces the risk of horizontal proliferation on the retina, while it induces intraretinal-vertical gliosis. The existence of these 2 gliosia types was shown in the research of Yvette i Dieter Ducournau [39]. The horizontal gliosis is connected to proliferation of astrocytes and Müller’s cells on the internal surface of the retina that subsequently leads to formation of epiretinal membranes. Vertical gliosis is connected to hypertrophy of Müller’s cells. Our aim is induction of vertical gliosis, while minimizing the gliosis on the retina’s surface. The effect of reactive, vertical gliosis after ILM removal allows for maintaining the blood-retina barrier and prevents macular edema installation. Wolf et al. [40] performed retinal histology via electron microscope after the internal limiting membrane was removed and demonstrated that a significant part of the Müller’s cells endings had been damaged. Their main bodies, however, did not show signs of damage. It is likely that the proliferation of GFAP-stained gliofibrils, observed in damaged Müller’s cells, preserves the blood-retinal barrier, reinforces architectural cohesion, and opposes the installation of the edema. Without question, a serious flaw connected with leaving parts of the ILM during vitrectomy is increased risk of developing secondary macular pucker syndrome.
in the meantime in order to facilitate the approximation of separated retinal layers that will result in restoration of synaptic connections between neurons. This offers a “therapeutic window” for both surgical and laser procedures in case of the recurrence of macular edema after surgery.

The limitation of the present study is that it included relatively small study numbers that may influence the statistical results, and that it lacked a control group. Larger prospective case series are needed to further evaluate the effect of triple therapy on diffused diabetic macular edema (DDME).

**REFERENCES:**

1. Moss S, Klein R, Klein B: The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998; 105: 998–1003
2. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol, 1985; 103: 1796–806
3. Quam T, Xu Q, Jousen AM et al: VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci, 2001; 42: 2408–13
4. Funatsu H, Yamashita H, Ikeda T et al: Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol, 2002; 133: 537–43
5. Kook D, Wolf A, Kreutzer T et al: Long-term effect of intravitreal bevacizumab (Avastin) in patients with chronic diffuse diabetic macular edema. Retina, 2008; 28: 1053–60
6. Nguyen QD, Shah SM, Khwaja AA et al., for the READ-2 Study Group: Two-year outcomes of the Ranibizumab for Edema of the macula in Diabetics (READ-2) study. Ophthalmology, 2010; 117: 2146–51
7. Scott IU, Edwards AR, Beck RW et al., Diabetic Retinopathy Clinical Research Network: A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology, 2007; 114: 1800–07
8. Arevalo JF, Fromow-Guerra J, Quirio-Mercado H et al., for the Pan-American Collaborative Retina Study Group: Primary intravitreal bevacizumab (Avastin) for diabetic macular edema. Ophthalmology, 2007; 114: 745–50
9. Saint-Geneix M, Maharaj AS, Walhe TE et al.: Endogenous VEGF is required for visual function: evidence for survival role on Müller cells and photoreceptors. Public Library of Science, 2008; 3: 3554
10. Hattenbach LO, Beck KF, Pfeilschifter J et al.: Pigment-Epithelium-Derived Factor Is Upregulated in Photocoagulated Human Retinal Pigment Epithelial Cells. Ophthalmic Research, 2003; 37: 541–46
11. Nasrallah FP, Jalkh AE, Van Coppenolle F et al.: The role of the vitreous in diabetic macular edema. Ophthalmology, 1988; 95: 1335–39
12. Nasrallah FP, Van De Velde F, Jalkh AE et al.: Importance of the vitreous in young diabetics with macular edema. Ophthalmology, 1989; 96: 1511–16
13. Ikeda T, Sato K, Katano T, Hayashi Y: Attached posterior hyaloid membranes and the pathogenesis of honeycombed cystoid macular edema in patients with diabetes. Am J Ophthalmol, 1999; 127: 478–79
14. Lewis H, Abrams GW, Blamenkranz MS, Campo RV: Vitrecomy for diabetic macular traction and edema associated with posterior hyaloid traction. Ophthalmology, 1992; 99: 753–59
15. Harbour JW, Smiddy WE, Flynn HW, Roubamen PE: Vitrecomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. Am J Ophthalmol, 1996; 121: 605–13
16. Gandorfer A, Messmer EM, Ullhag MW, Kampik A: Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. Retina, 2000; 20: 126–33
17. Sitt AW: The role of advanced glycation in the pathogenesis of diabetic retinopathy. Exp Mol Pathol, 2005; 78: 95–108
18. Lu M, Kuroki M, Amano S et al.: Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest, 1998; 101: 1219–24
19. Moore TC, Moore JE, Kaj Y et al.: The role of advanced glycation end products in retinal microvascular leukostasis. Invest Ophthalmol Vis Sci, 2003; 44: 4557–64
20. Barile GP, Pachydiplak SJ, Tari SR et al.: The RAGE Axis in Early Diabetic Retinopathy IOVS, 2005; 46: 2916–24
21. Nasrallah FP, Jalkh AE, Van Coppenolle F et al.: The role of the vitreous in diabetic macular edema. Ophthalmology, 1988; 95: 1335–39
22. Rungger-Brändle E, Dosso AA, Leuenberger PM: Gial reactivity, an early feature of diabetic retinopathy. Invest Ophthalmol Vis Sci, 2009; 41: 1971–80
23. Tout S, Chan-Ling T, Hollander H, Stone J: The role of Müller cells in the formation of the blood-retinal barrier. Neuroscience, 1995; 55: 291–301
24. Wolf S, Schnurbusch U, Wiedemann P et al.: Peeling of the basal membrane in the human retina: ultrastructural effects. Ophthalmology, 2004; 111(2): 238–43
25. Figueroa MS, Contreas I, Noval S: Surgical and anatomical outcomes of pars plana vitrectomy of diffuse nonproliferative diabetic macular edema. Retina, 2008; 28: 420–26
26. Harbour JW, Smiddy WE, Flynn HW, Roubamen PE: Vitrecomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. Am J Ophthalmol, 1996; 121: 605–13
27. Ikeda T, Sato K, Katano T, Hayashi Y: Vitrecomy for cystoid macular oedema with attached posterior hyaloid membrane in patients with diabetes. Br J Ophthalmol, 1999; 83: 12–14
28. Figueroa MS, Contreas I, Noval S: Surgical and anatomical outcomes of pars plana vitrectomy of diffuse nonproliferative diabetic macular edema. Retina, 2008; 28: 420–26
29. Patel JJ, Hykin PG, Schadi M et al.: Pars plana vitrectomy with and without peeling of the inner limiting membrane for diabetic macular edema. retina, 2006; 26: 5–13
30. Stensfass F, Landers MB, Wolbarsht ML: Increased retinal oxygen supply following pars-plana vitrectomy and vitrectomy and lenec- tomy. Trans Am Ophthalmol Soc, 1981; 79: 307–34
31. Nguyen QD, Shah SM, Van Anden E et al.: Supplemental oxygen improves diabetic macular edema: a pilot study. Invest Ophthalmol Vis Sci, 2004; 45: 617–24
32. Robaszkiewicz J, Chmielewska K, Wierzbowska J et al.: Combined surgical and pharmacological treatment of diabetic maculopathy. Klin Ocza, 2010; 11: 19–25
33. Kang SW, Park SC, Cho HY, Kang JE: Triple therapy of vitrecomy, intravitreal triamcinolone, and macular laser photoocoagulation for intractable diabetic macular edema. Am J Ophthalmol, 2007; 144: 878–85
34. Lee SS, Ghosn C, Yu Z et al.: Vitreous VEGF Clearence Is Increased after Vitrectomy. Investigative Ophthalmology and Visual Science, 2010; 51: 2135–38
35. Yeung L, Lima VC, Garcia P et al.: Correlation between Spectral Domain Optical Coherence Tomography Findings and Fluorescein Angiography Patterns in Diabetic Macular Edema. Ophthalmology, 2009; 116: 1158–67
36. Pendergast SD, Hassam TS, Williams GA et al.: Vitrecomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. Am J Ophthalmol, 2000; 130: 178–86
37. Jablonski MM, Tombran-Tink J, Mrazek DA, Iannaccone A: Pigment epithelium-derived factor supports normal Müller cell development and glutamine synthetase expression after removal of the retinal pigment epithelium. GLIA, 2001; 35: 14–25
38. Elman MJ, Aiello LP, Beck RW et al.: Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema and other retinal disorders. Am J Ophthalmol, 2002; 133: 537–43